Medidata Solutions, a global eClinical provider, announced that Australian contract research organization (CRO) Novotech has joined Medidata’s ASPire to Win channel partner program. As Australia’s largest full-service Australian CRO with extensive operations across Asia, Novotech can now offer sponsors a full range of services around the Medidata Rave electronic data capture (EDC) and clinical data management (CDM) solution.

Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of phase III trials. Novotech has helped global customers conduct trials across a population base of more than 1.5 billion people in the Australasian region. As the demand for global clinical outsourcing services continues to grow, Novotech selected Medidata Rave and joined the ASPire to Win program for Medidata’s ability to handle large, complex, global studies and its comprehensive partner enablement program.

“Medidata Rave is a robust system with global capabilities, a clear, intuitive interface and widespread acceptance among our global sites,” said Alek Safarian, CEO, Novotech. “Medidata also offers the technology and support that allows us to improve communication and streamline data collection and management with many of our clients based in North America and Europe, enabling us to drive global reach and close the distance gap.”

Novotech is now pursuing Rave Accredited Plus, the most advanced level in Medidata’s channel partner program. Once at this level, Novotech will be positioned to provide the full range of Rave-related services, including end-user training, study build, reporting, outputs, integrations and migrations.